Retrospective analysis of a random, nationally representative sample of inpatient discharges in the US from 2004 to 2006. Patients represent discharges from shortstay non-institutional hospitals in the US. Newborns and patients with an undefi ned payer status were excluded. Only patients with a routine or DAMA discharge status were included. A logistic regression analysis was performed modeling DAMA versus routine discharge as the outcome variable, with payer status as the primary predictor, and confounder variables, including gender, race, marital status, hospital type, geographic region, admission type and source, and drug abuse/addiction. Logistic regression analysis was also performed after removing drug/alcohol abuse/addiction patients. RESULTS: From 2004 to 2006 DAMA accounted for 1.23% (n 946,232) of all hospital discharges when drug and alcohol abuse/addiction patients are included and 0.76% (n 510,556) when excluded. Controlling for the confounder variables, public (AOR 0.72, 95% CI 0.61-0.80) and privately (AOR 0.46, 95% CI 0.40-0.52) insured patients are signifi cantly less likely to DAMA than self-pay patients. Consistent with the literature, males, African-Americans, private hospitals, emergency admissions, and drug (AOR 4.57,) and alcohol (AOR 5.00, 95% CI 4.46-5.61) abuse/addiction are signifi cant risk factors for DAMA. Many of these relationships become stronger when substance abuse cases are excluded. CONCLUSIONS: Considerable evidence exists that initiatives may be needed to better manage self-pay patients and ensure they do not DAMA. Further research should be done with longitudinal data to examine the relationship between DAMA and health outcomes. Prior research indicates that DAMA predictors may also be responsible for non-compliance of prescribed drug therapy, especially following discharge. Therefore the potential for early pharmacist involvement has also been identifi ed.
PHP69 PHARMACIST OPINION AND PERCEIVED CONFIDENCE IN KNOWLEDGE REGARDING THE IMPACT OF MEDICARE PART D PRESCRIPTION DRUG BENEFIT PROGRAM ON PATIENT CARE
Goyal R y , Makhija D, Sansgiry SS University of Houston, Houston, TX, USA OBJECTIVES: To determine pharmacist opinion regarding the impact of Medicare Part D prescription drug benefi t program (MPD) on patient care and evaluate their perceived confi dence in knowledge regarding MPD. Further, the study assessed pharmacists and practice site characteristics with their opinion and confi dence. METHODS: A prospective cross sectional survey (September 2006 to January 2007) was conducted using a convenient sample of 450 community pharmacists located in Houston. A scale of 0 (low) to 100 (high) was used to measure perceived confi dence consisting of 3 items. The instrument included 11 items on a 5 point Likert scale from strongly disagree (1) to strongly agree (5) to measure pharmacists opinion on MPD namely, patient satisfaction, quality of care, reimbursement gap, prescription coverage, dual eligibility and plan selection. Descriptive statistics and comparative analyses were performed with the coded data using SAS 9.1. RESULTS: The response rate was 52% (n 232). Mean ( SD) age of respondents was (36.7 7.6) years, with 50.9% male, 56% staff pharmacist, 94% practicing in chain pharmacy, and 61.6% practicing for less than 10 years. Overall, pharmacists were confi dent (78 16.0) in their knowledge about MPD. Pharmacist's opinion in general was slightly positive (3.5 0.5) regarding the infl uence of MPD on patient care. Signifi cant differences (p 0.05) were observed by gender (male 82 vs. female75.4) and degree earned (BS 74 vs. PharmD 82.5) with respect to their confi dence regarding MPD, respectively. Practice settings and pharmacist current positions did not seem to infl uence their confi dence regarding MPD. Pharmacists perceived confi dence was signifi cantly correlated (p 0.05, r 0.414) with their opinion regarding patient care domains of MPD. CONCLUSIONS: Pharmacist's characteristics play a role in their perceived confi dence regarding their knowledge about MPD. Opinions regarding pharmacists on MPD aspects that would affect patient care were consistent across pharmacist characteristics and practice setting. associated with decreased ED visits among persons with employer-based health insurance, but not with a decrease in the odds for a fi rst ED visit. CONCLUSIONS: Programs to decrease ED use, such as cost-sharing, have been evaluated, but studies to evaluate these types of policies have typically focused on insured individuals. As a result, there is an important gap in understanding the epidemiology and economics of ED use among low-income, uninsured, and underinsured persons.
PHP70 ASSESSING THE EFFECT OF COST-SHARING ON EMERGENCY DEPARTMENT USE BY ECONOMICALLY DISADVANTAGED PERSONS

PHP71 HOW DO MANAGED PHYSICIAN PANELS COMPARE AGAINST NON-PANEL PHYSICIANS FOR THE PURPOSE OF RESEARCH?
Narayanan S y TNS Healthcare, New York, NY, USA OBJECTIVES: Clinical investigator databases, prescriber-list and ad-hoc sources often constitute the physician pool for epidemiological and outcomes-research initiatives. Use of "managed physician panels" for such research purpose is not yet common. This study aims to compare demographics, prescribing patterns and attitudes/ opinions between physicians in 'managed panels' and free-bound non-panel sample in the U.S. METHODS: TNS manages J-Street Panel, a managed panel of over 25,000 physicians in the U.S across 35 specialties. A small proportion of these physicians, especially allergists/pulmonologists, were recruited online, and another cohort from free-bound (non-panel) sample was recruited via telephone for a research initiative. Practice characteristics, treatment dynamics and attitudes/opinions were measured in both cohorts using a standardized 30-minute-survey; the results were analyzed to assess any statistical difference between the panelists and non-panelists across the measured domains. RESULTS: Survey results from allergists/pulmonologists (83-panelists & 68-non-panelists) specifi cally in the COPD/Asthma categories were assessed. There were no statistically signifi cant differences observed between the cohorts in practice characteristics: percent of time spent in clinical practice, number of COPD and/or Asthma patients seen in a typical month, percent of COPD patients with no asthma, and percent of asthma patients with no COPD, with years of clinical-practice alone differing between cohorts (panelists-14 yrs/non-panelists-17 yrs); no differences observed in treatment choices (including, percent of patients prescribed a maintenance medication for their asthma and/or COPD) and treatment practices (9-item-domain), with the same prescribing levels holding true across all medications and dosage strengths. CONCLUSIONS: This is one of the fi rst studies to quantitatively compare managed panel of physicians to their non-panel counterparts in the U.S and the results showed no statistical differences between the cohorts in the measured domains. Managed panels are viable options for scientifi c research studies, as they provide robust, cost-effective, quick sample of physicians, with relatively high response rate.
PHP72
PATIENT PRIVACY AND DATA CONFIDENTIALITY AND THE USE OF SECONDARY DATA Dean BB 1 , Aguilar D 1 , Whyte J 2 , Nordyke R 2 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 Amgen, Inc., Thousand Oaks, CA, USA OBJECTIVES: No well-defi ned standards, including provisions in HIPAA, currently provide clear guidance for merging, linking, and analyzing secondary health data that were originally collected for patient care, such as electronic medical record (EMR) data. A literature review explored factors that may affect potential risks of secondary data research from the perspective of patient privacy and data con fi dentiality. METHODS: The PubMed database and internet sites of CDC, DHHS, and patient advocacy groups were searched to identify publications from January 1, 1998 to March 7, 2008 involving patient privacy and secondary use of data. Search terms included (but were not limited to): confi dentiality, privacy, consent, ethics, secondary data, secondary analysis, patient data, de-identifi ed, and identifi able. RESULTS: A total of 33 documents were identifi ed. Several discussion topics that address patient privacy within the context of secondary data research were identifi ed in the literature. These issues were assessed and grouped into four domains: 1) concerns about inadequacy of patient consent [76% of articles] (eg, no patient consent is needed or that consent obtained for general research purposes may not be adequate for specifi c research hypotheses); 2) concerns about identifi ability of the data and the degree to which the data can be de-identifi ed [88%]; 3) concerns about data access, including monitoring, controlling, and regulation of data access [85%]; and (4) concerns about the investigators' objectives for analyzing and using the data [52%] (eg, epidemiology and surveillance studies caused less concern than did market research). CONCLUSIONS: We identifi ed four recurrent themes in the evidence: they touched upon patient consent, identifi ability of data, data access, and research objectives. Dialogue about these issues between investigators, research oversight administrators and patient advocates may help clarify standards to ensure that secondary data research is broadly acceptable from a patient privacy and data confi dentiality perspective.
